

Trust Headquarters  
 Russell's Hall Hospital  
 Dudley  
 West Midlands  
 DY1 2HQ

**Ref:** FOI-022026-0002212

**Date:** 12.03.2026

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **39**
- Abemaciclib + Fulvestrant **7**
- Alpelisib + Fulvestrant **0**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only **21**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel **0**
- Atezolizumab **1**
- Capivasertib **1**
- Capecitabine as a single agent **7**
- Carboplatin + Paclitaxel **1**
- Elacestrant **3**
- Eribulin as a single agent or in combination **2**
- Everolimus + Exemestane **0**
- Fulvestrant as a single agent **6**
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **42**
- Palbociclib + Fulvestrant **3**
- Parp Inhibitors (Olaparib/Talazoparib) **1**
- Pembrolizumab Monotherapy **9**
- Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide **7**
- Carboplatin + Paclitaxel + Pembrolizumab **4**
- Pertuzumab (Perjeta) + Trastuzumab (Herceptin) **1**
- Phesgo (Pertuzumab + Trastuzumab in a single injection) **32**
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **52**
- Ribociclib + Fulvestrant **7**
- Sacituzumab Govitecan **4**
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent **20**
- Trastuzumab deruxtecan (Enhertu) **12**
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel **35**
- Trastuzumab emtansine (Kadcyla) **15**
- Any other active systemic anti-cancer therapy **19**

Q2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)	32	18	14
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	1	1	0
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	35	31	4
Trastuzumab deruxtecan (Enhertu)	12	2	10
Trastuzumab emtansine (Kadcyla)	15	14	1
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	39	31	8
Abemaciclib + Fulvestrant	7	2	5
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	52	34	18
Ribociclib + Fulvestrant	7	0	7
Capecitabine as a single agent	7	1	6
Carboplatin + Paclitaxel	1	0	1
Carboplatin + Paclitaxel + Pembrolizumab	4	4	0

Q3. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

**ADD-Aspirin – 1 patient**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team  
The Dudley Group NHS Foundation Trust**